Published in final edited form as:

J Am Chem Soc. 2019 March 20; 141(11): 4547–4552. doi:10.1021/jacs.9b00044.

Redox-Controlled Site-Specific α 2–6-Sialylation

Na Lu[†], Jinfeng Ye[†], Jiansong Cheng[‡], Aniruddha Sasmal[§], Chang-Cheng Liu^{†,‡},
Wenlong Yao[†], Jun Yan[†], Naazneen Khan[§], Wen Yi[#], Ajit Varki[§], Hongzhi Cao^{†,‡}

[†]National Glycoengineering Research Center, State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, China

[‡]College of Pharmacy, Nankai University, Tianjin 300071, China

[§]Glycobiology Research and Training Center, University of California, San Diego, California 92093, USA

[‡]Key Laboratory of Chemical Biology of Ministry of Education, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China

[#]Institute of Biochemistry, College of Life Sciences, Zhejiang University, Hangzhou 310058, China

Abstract

The first bacterial α 2–6-sialyltransferase cloned from *Photobacterium damsela* (Pd2,6ST) has been widely applied for the synthesis of various α 2–6-linked sialosides. However, the extreme substrate flexibility of Pd2,6ST makes it unsuitable for site-specific α 2–6-sialylation of complex substrates containing multiple galactose and/or *N*-acetylgalactosamine units. To tackle this problem, a general redox-controlled site-specific sialylation strategy using Pd2,6ST is described. This approach features site-specific enzymatic oxidation of galactose units to mask the unwanted sialylation sites and precisely controlling the site-specific α 2–6-sialylation at intact galactose or *N*-acetylgalactosamine units.

Graphical Abstract

Corresponding Author: hzcaos@sdu.edu.cn.

These authors contributed equally.

ASSOCIATED CONTENT

Supporting Information. Detailed experimental procedures and product characterization. This material is available free of charge via the Internet at <http://pubs.acs.org>

The authors declare no competing financial interests.

Sialic acids (Sias) are the most common termini and among the most abundant monosaccharides of mammalian glycans.¹ As ubiquitous components of glycoproteins and glycolipids, three common sialic acids of *N*-acetylneuraminic acid (Neu5Ac, **1**), *N*-glycolylneuraminic acid (Neu5Gc, **2**) and 2-keto-3-deoxy-nonulosonic acid (Kdn, **3**) are found α 2–6-linked to galactose (Gal) or *N*-acetylgalactosamine (GalNAc) residues (Scheme 1a). Owing to their remarkable structural diversity, sialic acid-containing glycans play important roles in many physiological and pathological processes, and most sialic acid-related biological processes require specific sialic acid forms, glycosidic linkage and defined underlying glycan chains.² For example, avian influenza viruses primarily bind to α 2–3-linked sialic acid, whereas human influenza viruses preferentially recognize α 2–6-linked sialic acid.³ Recent studies also demonstrated that α 2–6-sialylation is required for the anti-inflammatory activities of intravenous immunoglobulin (IVIG), and *in vitro* glycoengineered IVIG with uniform α 2–6-sialylated *N*-glycans showed 10-fold enhancement in anti-inflammatory activities compared to unfractionated IVIG.⁴ It is also well known that the high expression levels of α 2–6-sialylated glycans on a number of carcinomas are correlated with cancer progression and poor prognosis.^{2b, 5}

The past few decades have witnessed increasing attention on using glycosyltransferases for the synthesis of various glycans and glycoconjugates.⁶ However, only very few recombinant sialyltransferases (SiaTs) from both mammals and bacteria have been widely applied for the construction of both α 2–6-sialyl linkages **4** and **5**, (Scheme 1a). ST6Gal I is a mammalian α 2–6-SiaT which has been widely used for the α 2–6-sialylation of terminal Gal residue, but it has very strict substrate specificity that can only use terminal type-2 glycan (Gal β 1–4GlcNAc) as acceptor substrate (Scheme 1b, i).⁷ ST6GalNAc I is another recombinant mammalian α 2–6-SiaT which has been used for the α 2–6-sialylation of GalNAc residue, but it can only use Tn antigen or T antigen as acceptor substrates (Scheme 1b, i).⁸ The α 2–6-sialylation of terminal Gal residues of type-1 glycan (Gal β 1–3GlcNAc) and LacdiNAc (GalNAc β 1–4GlcNAc) have also been identified in a number of naturally occurring glycans⁹, however, the SiaTs responsible for the α 2–6-sialylation modification are still unknown. Moreover, α -series cholinergic neuron-specific gangliosides, a subgroup of gangliosides with α 2–6-sialylation on the GalNAc residue of extended type 1 glycan chain, play important roles in the development and regeneration of nervous system.¹⁰ However, due

to the substrate restriction and unavailability of siaT for modification of GalNAc residue, none of these complex sialoglycans have been enzymatically synthesized yet.¹¹

In contrast to mammalian α 2–6-SiaTs, the first recombinant bacterial α 2–6-SiaT cloned from *Photobacterium damsela* (Pd2,6ST) can be overexpressed in a conventional *E. coli* strain.¹² Owing to its remarkable activity and extreme substrate specificities, the Pd2,6ST has been extensively used for the construction of both Sia α 2–6Gal and Sia α 2–6GalNAc sequences for the synthesis of various *O*-glycans, *N*-glycans and human milk oligosaccharides.^{7d, 12a, 13} Unfortunately, previous studies shown that the Pd2,6ST can recognize both internal and terminal Gal and GalNAc moieties of complex substrates, resulting a mixture of sialylated products (Scheme 1b, ii).^{7d, 13c–g} To overcome the limitations of both mammalian and bacterial α 2–6-SiaTs, we describe herein a novel redox-controlled site-specific α 2–6-sialylation approach to precisely control the reaction sites of Pd2,6ST for the synthesis of complex α 2–6-linked sialosides (Scheme 1c).

To validate the feasibility of our proposed redox-controlled site-specific α 2–6-sialylation strategy, lacto-*N*-neohexaoside (LNnH) **11** containing three Gal residues (Scheme 2) was investigated first as a model substrate. LNnH potentially has seven α 2–6-sialylated products, including three mono-sialylated heptasaccharides **17**, **19** and **29**, and three di-sialylated octasaccharides **22**, **26** and **32**. Galactose oxidase (GOase), a commercially available copper metalloenzyme, has been widely used in biosensor for detecting Gal or terminal Gal-containing glycans by selective oxidation of the C6-hydroxyl group of free galactose or terminal Gal residue into C6-aldehyde galactose (Gal^{6-Ald}).¹⁴ The resulting C6-aldehyde group has also been extensively used as a chemical handle for further labelling and derivatization purposes.^{14–15} We envisioned that the Gal^{6-Ald} would act as a protected Gal residue and would not be sialylated by Pd2,6ST. Therefore, the site-specific introduction of α 2–6-linked sialic acid to the intact Gal residues could be achieved. To obtain mono-sialylated heptasaccharide **17** with an α 2–6-linked sialic acid at non-reducing end of hexasaccharide **11**, both internal Gal residues of **11** need to be protected by oxidation, while the terminal Gal was left intact for site-specific α 2–6-sialylation. As shown in Scheme 2, lactoside **12** was treated with oxidation module in the presence of GOase and peroxidase to convert the terminal Gal residue into Gal^{6-Ald}. The resulting disaccharide was then extended by a one-pot three-enzyme β 1–3-*N*-acetylglucosaminylation module (EM1)^{13b, 13d} to give trisaccharide **13** in 73% yields for 2 steps. Trisaccharide **13** was elongated by a β 1–4-linked Gal using enzyme module 2 (EM2)^{13b, 13d}, and the nascent terminal Gal was also converted into Gal^{6-Ald} by oxidation module, and then extended by sequential glycosylation with EM1 and EM2 to afford the hexasaccharide intermediate **15**. Although, all C6-aldehyde groups of oxidized Gal moieties exist as hydrated geminal diols, none of them could be utilized by Pd2,6ST in EM3^{13b, 13d} as sialylation site. The mono-sialylated **16** was isolated as only product in 94% yield. Two Gal^{6-Ald} residues of **16** can be reduced back to the Gal moieties by simply treating with NaBH₄ in aqueous solution to provide mono-sialylated heptasaccharide **17** in 98% yield. The same redox-controlled site-specific α 2–6-sialylation strategy was also successfully applied in the synthesis of mono-sialylated heptasaccharide **19**, di-sialylated octasaccharides **22** and **26** using corresponding Gal^{6-Ald}-containing glycans as intermediates. The syntheses of mono-sialylated heptasaccharide **29** and di-sialylated

Author Manuscript

octasaccharide **32** can be realized by simply changing the glycosylation sequence of three same enzyme modules (EM1-EM3) without the need of oxidation module (Scheme 2).

The Sia α 2–6Gal sequence is not only a common terminal component of various *N*-, *O*-glycans and glycolipids, but also has been identified as internal moieties in a number of naturally occurring glycans.^{9d, 16} However, the SiaT from either mammalian or bacteria source that can catalyze site-specific α 2–6-sialylation at the internal Gal is still unknown. The redox-controlled α 2–6-sialylation strategy provides a practical approach to harness the extreme substrate flexibility offered by readily available bacterial sialyltransferase Pd2,6ST, thus provides the first synthetic approach for on demand site-specific α 2–6-sialylation of poly-LacNAc glycans.

Author Manuscript

This redox-controlled site-specific α 2–6-sialylation strategy also provides an easy access for the synthesis of complex sialosides bearing different α 2–6-linked sialic acid forms. As shown in Scheme 3a, the tetrasaccharide **24** with a terminal Gal^{6-Ald} was extended using EM1, then the innermost intact Gal was modified with an α 2–6-linked Neu5Gc using EM3 in the presence of Neu5Gc as the donor precursor to give hexasaccharide **34**. The **34** was treated with EM2 to form a LacNAc termini which was further modified with an α 2–6-linked Neu5Ac by EM3 in the presence of Neu5Ac as the donor precursor to afford intermediate **35**. The Gal^{6-Ald} moiety of **35** was reduced back to Gal by NaBH₄ to give disialyl octasaccharide **36** containing hybrid sialic acid forms in excellent overall yields. Taking advantage of this redox-controlled site-specific sialylation strategy, octasaccharide **38** with two different sialic acid forms, and nonasaccharide **39** with three different sialic acid forms at designated positions were also achieved from **24** (Scheme 3a). Moreover, a one-pot two-enzyme α 2–8-sialylation enzyme module (EM4) comprising a recombinant α 2–8-sialyltransferase from *Campylobacter jejuni* (CjCstII)¹⁷ was applied for the modification of innermost α 2–6-linked Neu5Ac to produce nonasaccharide **42** and **45** in good overall yields, respectively (Scheme 3a, see Supporting Information for details).

Author Manuscript

Having established the redox-controlled site-specific α 2–6-sialylation strategy for poly-LacNAc glycan receptors, the substrate scope and general applicability of the strategy was explored next. As shown in Scheme 3b, the terminal GlcNAc moiety of trisaccharide **13** was parallelly elaborated to type 2 chain by EM2 to give **14**, type 1 chain by EM5 to give **48**, and LacdiNAc by EM6 to give **51**, respectively. In addition to bacterial β 1–4GalT NmLgtB in EM2, the recombinant β 1–3GalT from *E. coli* (EcWbgO)¹⁸ in EM5, and recombinant bovine GalT 1 mutant (GalT1 Y289L)¹⁹ in EM6 all utilize trisaccharide **13** as receptor efficiently. As anticipated, the extreme substrate flexibility of Pd2,6ST in EM3 ensured the α 2–6-sialylation at the terminal Gal of **14** and **48**, and terminal GalNAc of **51** furnishing pentasaccharides **46**, **49** and **52**, which were then treated with NaBH₄ to give the sialyl LNT (LSTc) **47**, sialyl LNT **50** and sialyl LacdiNAc (sialyl LDNT) **53** in excellent yields, respectively (Scheme 3b). The GOase can also selectively oxidize the terminal GalNAc unit. Therefore, the selective oxidation of terminal GalNAc unit of LDNT **54** could achieve site-specific α 2–6-sialylation at the internal Gal. After reduction, the mono-sialylated LDNT **57** was obtained in 69% overall yields for 3 steps (Scheme 3c).

The redox-controlled sialylation strategy could also be applied for the site-specific α 2–6-sialylation of internal GalNAc residue for the synthesis of sialyl GNB **61**, di-sialyl GNB **62** and α -series ganglioside glycan GM1 α **65**. It was shown that the Pd2,6ST could modify both Gal and GalNAc residues of GNB **58a** or **58b**, resulting in a mixture of two mono-sialylated and one di-sialylated products for each of them (Scheme 1b, ii).^{13f} For site-specific α 2–6-sialylation at internal GalNAc residue, the terminal Gal of **58a** or **58b** was converted into Gal^{6-Ald} by oxidation enzyme module to give **59a** or **59b**. Both **59a** or **59b** were treated with α 2–6-sialylation module EM3, however, only **59b** could be utilized by Pd2,6ST to afford the sialoside **60**. These results were consistent with previous report that the α -linked GalNAc is not a good substrate for Pd2,6ST.^{12a} Sialoside **60** was reduced with NaBH₄ to afford sialyl GNB **61** in 73% yields for 3 steps. The **61** could be further elaborated to di-sialyl GNB **62** by an α 2–3-sialylation enzyme module (EM7)^{13b, 20} (Scheme 3d).

As aforementioned, owing to the substrate restriction and unavailability of siaT for modification of GalNAc residue, none of α -series cholinergic neuron-specific gangliosides has been enzymatically synthesized yet. The first enzymatic synthesis of α -series ganglioside glycan GM1 α **65** using redox-controlled sialylation strategy was also explored. Starting from known asialo-GM1 (GA1) **63**²¹, a similar sequence involving enzymatic oxidation, selective α 2–6-sialylation of internal GalNAc, and subsequent reduction provided ganglioside GM1 α **65** in 74% yields for 3 steps (Scheme 3e). Interestingly, the Pd2,6ST in EM3 can only introduce α 2–6-linked Neu5Ac at GalNAc residue to give pentasaccharide **64**, while sialylation of innermost Gal residue was not observed. The redox-controlled sialylation strategy utilized for the synthesis of GM1 α **65** provides a novel approach for the synthesis of other α -series gangliosides. Besides, by replacing NaBH₄ with NaBD₄ in the reduction step, the Gal^{6-Ald}-containing intermediates in this study, such as **64**, can be transformed into deuterium labeled products (e.g. GM1 α **66**), which could be used as probe in elucidating multiple biochemical processes (Scheme 3d, see Supporting Information for details).

The binding profiles of synthesized sialosides with sialic acid-recognition proteins were also examined using printed sialoglycan slides. The plant lectin *Sambucus nigra* agglutinin (SNA) is known to be able to specifically recognize α 2–6-linked sialosides.²² SNA exhibited very strong binding exclusively to all sialosides with a terminal α 2–6-sialylated LacNAc moiety, while no significant binding was observed for internal α 2–6-sialylated glycans (Figure S7). Chicken polyclonal anti-Neu5Gc antibody IgY (pChGc) bound to all Neu5Gc-containing glycans with a preference toward terminal α 2–6-linked Neu5Gc (Figure S8). In contrast, human anti-Neu5Gc antibody rich serum only bound tightly with terminal α 2–6-linked Neu5Gc (Figure S9). The His-tagged typhoid toxin (PltB-His) recognized all Neu5Ac modified glycans (Figure S10), while human sialic acid-binding lectin Siglec-9 (hSiglec-9-Fc) only bound tightly to terminal Neu5Ac-modified glycans and Neu5Aca α 2–8Neu5Aca α 2–6-linked glycan (Figure S11). Plant lectins *Maackia amurensis* lectin I and II (MAL-I-II) were also examined. As expected only α 2–3-linked sialoside **62** exhibited strong affinity to MAL-II (Figure S12–S13).²²

In summary, a novel substrate engineering strategy²³ was developed to harness the extreme substrate flexibility of Pd2,6ST for site-specific α 2–6-sialylation of both Gal and GalNAc residues of various substrates. This strategy overcomes the limitation of availability and substrate specificities of known mammalian and bacterial α 2–6-sialyltransferases, thereby providing a general and concise approach for the synthesis of complex α 2–6-sialylated glycans with a single bacterial α 2–6-sialyltransferase Pd2,6ST.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENT

We thank Prof. Xi Chen at the University of California at Davis for sharing plasmids and providing helpful discussions, and Sandra Diaz at UCSD for technical help. This project was financially supported by National Natural Science Foundation of China (Grant Nos. 21672128, 21877072, 21807064), State Key Laboratory of Microbial Technology (M2016–06), Department of Science and Technology of Shandong Province (2016GGH4502, 2016GSF121002, ZR201709190252), Shandong University (2018JC053) and NIH grant R01GM32373.

REFERENCES

- Werz DB; Ranzinger R; Herget S; Adibekian A; von der Lieth C-W; Seeberger PH, Exploring the structural diversity of mammalian carbohydrates (“glycospace”) by statistical databank analysis. *ACS Chem. Biol* 2007, 2, 685–691. [PubMed: 18041818]
- a)Chen X; Varki A, Advances in the biology and chemistry of sialic acids. *ACS Chem. Biol* 2010, 5, 163–176; [PubMed: 20020717] b)Varki A, Sialic acids in human health and disease. *Trends Mol. Med* 2008, 14, 351–360; [PubMed: 18606570] c)Angata T; Varki A, Chemical diversity in the sialic acids and related α -keto acids: an evolutionary perspective. *Chem. Rev* 2002, 102, 439–470; [PubMed: 11841250] d)Schauer R, Achievements and challenges of sialic acid research. *Glycoconj. J* 2000, 17, 485–499. [PubMed: 11421344]
- Rogers G; Paulson J; Daniels R; Skehel J; Wilson I; Wiley D, Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity. *Nature* 1983, 304, 76. [PubMed: 6191220]
- Anthony RM; Nimmerjahn F; Ashline DJ; Reinhold VN; Paulson JC; Ravetch JV, Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. *Science* 2008, 320, 373–376. [PubMed: 18420934]
- a)Rodrigues E; Macauley M, Hypersialylation in cancer: modulation of inflammation and therapeutic opportunities. *Cancers* 2018, 10, 207;b)Büll C; Stael MA; den Brok MH; Adema GJ, Sialic acids sweeten a tumor’s life. *Cancer Res* 2014, 74, 3199–3204. [PubMed: 24830719]
- a)For recent reviews, see: Wen L; Edmunds G; Gibbons C; Zhang J; Gadi MR; Zhu H; Fang J; Liu X; Kong Y; Wang PG, Toward automated enzymatic synthesis of oligosaccharides. *Chem. Rev* 2018, 118, 8151–8187; [PubMed: 30011195] b)Yu CC; Withers SG, Recent developments in enzymatic synthesis of modified sialic acid derivatives. *Adv. Syn. Catal* 2015, 357, 1633–1654;c)Schmaltz RM; Hanson SR; Wong C-H, Enzymes in the synthesis of glycoconjugates. *Chem. Rev* 2011, 111, 4259–4307; [PubMed: 21749134] d)Palcic MM, Glycosyltransferases as biocatalysts. *Curr. Opin. Chem. Biol* 2011, 15, 226–233. [PubMed: 21334964]
- a)Moremen KW; Ramiah A; Stuart M; Steel J; Meng L; Forouhar F; Moniz HA; Gahlay G; Gao Z; Chapla D, Expression system for structural and functional studies of human glycosylation enzymes. *Nature Chem. Biol* 2018, 14, 156–162; [PubMed: 29251719] b)Prudden AR; Liu L; Capicciotti CJ; Wolfert MA; Wang S; Gao Z; Meng L; Moremen KW; Boons G-J, Synthesis of asymmetrical multiantennary human milk oligosaccharides. *Proc. Natl. Acad. Sci. USA* 2017, 114, 6954–6959; [PubMed: 28630345] c)Wang Z; Chinoy ZS; Ambre SG; Peng W; McBride R; de Vries RP; Glushka J; Paulson JC; Boons G-J, A general strategy for the chemoenzymatic

synthesis of asymmetrically branched N-glycans. *Science* 2013, 341, 379–383; [PubMed: 23888036] d)Nycholat CM; Peng W; McBride R; Antonopoulos A; de Vries RP; Polonskaya Z; Finn M; Dell A; Haslam SM; Paulson JC, Synthesis of biologically active N- and O-linked glycans with multisialylated poly-N-acetyllactosamine extensions using *P. damsela* α 2–6 sialyltransferase. *J. Am. Chem. Soc* 2013, 135, 18280–18283. [PubMed: 24256304]

- (8). a)For selected examples, see: Blixt O; Allin K; Pereira L; Datta A; Paulson JC, Efficient chemoenzymatic synthesis of O-linked sialyl oligosaccharides. *J. Am. Chem. Soc* 2002, 124, 5739–5746; [PubMed: 12010048] b)George SK; Schwientek T; Holm B; Reis CA; Clausen H; Kihlberg J, Chemoenzymatic synthesis of sialylated glycopeptides derived from mucins and T-cell stimulating peptides. *J. Am. Chem. Soc* 2001, 123, 11117–11125. [PubMed: 11697954]
- (9). a)Anugraham M; Jacob F; Nixdorf S; Everest-Dass AV; Heinzelmann-Schwarz V; Packer NH, Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status. *Mol. Cell. Proteomics* 2014, 13, 2213–2232; [PubMed: 24855066] b)Saarinen J; Welgus HG; Flizar CA; Kalkkinen N; Helin J, N-Glycan structures of matrix metalloproteinase-1 derived from human fibroblasts and from HT-1080 fibrosarcoma cells. *Eur. J. Biochem* 1999, 259, 829–840; [PubMed: 10092871] c)Suzuki Y; Nakao T; Ito T; Watanabe N; Toda Y; Guiyun X; Suzuki T; Kobayashi T; Kimura Y; Yamada A, Structural determination of gangliosides that bind to influenza A, B, and C viruses by an improved binding assay: strain-specific receptor epitopes in sialo-sugar chains. *Virology* 1992, 189, 121–131; [PubMed: 1376537] d)Podolsky DK, Oligosaccharide structures of isolated human colonic mucin species. *J. Biol. Chem* 1985, 260, 15510–15515; [PubMed: 4066681] e)Mizuochi T; Yamashita K; Fujikawa K; Kisiel W; Kobata A, The carbohydrate of bovine prothrombin. Occurrence of Gal β 1,3-GlcNAc grouping in asparagine-linked sugar chains. *J. Biol. Chem* 1979, 254, 6419–6425. [PubMed: 447725]
- (10). Yang L; Zeller CB; Shaper NL; Kiso M; Hasegawa A; Shapiro RE; Schnaar RL, Gangliosides are neuronal ligands for myelin-associated glycoprotein. *Proc. Natl. Acad. Sci. USA* 1996, 93, 814–818. [PubMed: 8570640]
- (11). a)Hotta K; Komba S; Ishida H; Kiso M; Hasegawa A, Synthetic studies on sialoglycoconjugates 61: synthesis of α -series ganglioside GM1 α . *J. Carbohydr. Chem* 1994, 13, 665–677; b)Prabhanjan H; Aoyama K; Kiso M; Hasegawa A, Synthesis of disialoganglioside GD1 α and its positional isomer. *Carbohydr. Res* 1992, 233, 87–99; [PubMed: 1446313] c)Prabhanjan H; Kiso M; Hasegawa A, Total synthesis of a disialoganglioside GD1 α . *Carbohydr. Res* 1991, 222, C1–C4. [PubMed: 1813100]
- (12). a)Yu H; Huang S; Chokhawala H; Sun M; Zheng H; Chen X, Highly efficient chemoenzymatic synthesis of naturally occurring and non-natural α -2,6-linked sialosides: a *P. damsela* α -2,6-sialyltransferase with extremely flexible donor-substrate specificity. *Angew. Chem. Int. Ed* 2006, 45, 3938–3944; b)Yamamoto T; Nakashizuka M; Terada I, Cloning and expression of a marine bacterial β -galactoside α 2,6-sialyltransferase gene from *Photobacterium damsela* JT0160. *J. Biochem* 1998, 123, 94–100. [PubMed: 9504414]
- (13). a)For selected examples, see: Yu H; Yan X; Autran CA; Li Y; Etzold S; Latasiewicz J; Robertson BM; Li J; Bode L; Chen X, Enzymatic and chemoenzymatic syntheses of disialyl glycans and their necrotizing enterocolitis preventing effects. *J. Org. Chem* 2017, 82, 13152–13160; [PubMed: 29124935] b)Yu H; Chen X, One-pot multienzyme (OPME) systems for chemoenzymatic synthesis of carbohydrates. *Org. Biomol. Chem* 2016, 14, 2809–2818; [PubMed: 26881499] c)Shivatare SS; Chang S-H; Tsai T-I; Tseng SY; Shivatare VS; Lin Y-S; Cheng Y-Y; Ren C-T; Lee C-CD; Pawar S; Tsai C-S; Shih H-W; Zeng Y-F; Liang C-H; Kwong PD; Burton DR; Wu C-Y; Wong C-H, Modular synthesis of N-glycans and arrays for the hetero-ligand binding analysis of HIV antibodies. *Nature Chem* 2016, 8, 338–346; [PubMed: 27001729] d)Chen C; Zhang Y; Xue M; Liu XW; Li Y; Chen X; Wang PG; Wang F; Cao H, Sequential one-pot multienzyme (OPME) synthesis of lacto-N-neotetraose and its sialyl and fucosyl derivatives. *Chem. Commun* 2015, 51, 7689–7692; e)Yu H; Lau K; Thon V; Autran CA; Jantscher-Krenn E; Xue M; Li Y; Sugiarto G; Qu J; Mu S; Ding L; Bode L; Chen X, Synthetic disialyl hexasaccharides protect neonatal rats from necrotizing enterocolitis. *Angew. Chem. Int. Ed* 2014, 53, 6687–6691; f)Meng X; Yao W; Cheng J; Zhang X; Jin L; Yu H; Chen X; Wang F; Cao H, Regioselective chemoenzymatic synthesis of ganglioside disialyl tetrasaccharide epitopes. *J. Am. Chem. Soc* 2014, 136, 5205–5208; [PubMed: 24649890] g)Chien WTL, C. F.; Yu CC; Lin CH;

Li SP; Primadona I; Chen YJ; Mong KK; Lin CC, Sequential one-pot enzymatic synthesis of oligo-N-acetylglucosamine and its multi-sialylated extensions. *Chem. Commun* 2014, 50, 5786–5789;h)Malekan H; Fung G; Thon V; Khedri Z; Yu H; Qu J; Li Y; Ding L; Lam KS; Chen X, One-pot multi-enzyme (OPME) chemoenzymatic synthesis of sialyl-Tn-MUC1 and sialyl-T-MUC1 glycopeptides containing natural or non-natural sialic acid. *Bioorg. Med. Chem* 2013, 21, 4778–4785; [PubMed: 23535562] i)Teo CF; Hwang TS; Chen PH; Hung CH; Gao HS; Chang LS; Lin CH, Synthesis of sialyl TN glycopeptides-enzymatic sialylation by α 2,6-sialyltransferase from *Photobacterium damsela*. *Adv. Syn. Catal* 2005, 347, 967–972;j)Kajihara Y; Yamamoto T; Nagae H; Nakashizuka M; Sakakibara T; Terada I, A novel α -2,6-sialyltransferase: transfer of sialic acid to fucosyl and sialyl trisaccharides. *J. Org. Chem* 1996, 61, 8632–8635.

- (14). a)Parikka K; Master E; Tenkanen M, Oxidation with galactose oxidase: multifunctional enzymatic catalysis. *J. Mol. Catal. B* 2015, 120, 47–59;b)Rannes JB; Ioannou A; Willies SC; Grogan G; Behrens C; Flitsch SL; Turner NJ, Glycoprotein labeling using engineered variants of galactose oxidase obtained by directed evolution. *J. Am. Chem. Soc* 2011, 133, 8436–8439. [PubMed: 21526835]
- (15). a)Laaf D; Bojarová P; Pelantova H; Kren V; Elling L, Tailored multivalent neo-glycoproteins: synthesis, evaluation, and application of a library of galectin-3-binding glycan ligands. *Bioconj. Chem* 2017, 28, 2832–2840;b)Kupper CE; Rosencrantz RR; Henßen B; Pelantová H; Thönes S; Drozdová A; K en V; Elling L, Chemo-enzymatic modification of poly-N-acetylglucosamine (LacNAc) oligomers and N,N-diacetylglucosamine (LacDiNAc) based on galactose oxidase treatment. *Beilstein J. Org. Chem* 2012, 8, 712–725. [PubMed: 23015818]
- (16). a)Naumenko OI; Zheng H; Sof'ya NS; Wang H; Li Q; Shashkov AS; Wang J; Knirel YA; Xiong Y, Structures and gene clusters of the O-antigens of *Escherichia albertii* O3, O4, O6, and O7. *Carbohydr. Res* 2017, 449, 17–22; [PubMed: 28672166] b)Deutschmann R; Boncheff AG; Daraban L; MacInnes JI; Monteiro MA, Common sialylated glycan in *Actinobacillus suis*. *Glycobiology* 2010, 20, 1227–1232; [PubMed: 20501522] c)Eserstam R; Rajaguru TP; Jansson PE; Weintraub A; Albert MJ, The structure of the O-chain of the lipopolysaccharide of a prototypal diarrheagenic strain of *Hafnia alvei* that has characteristics of a new species under the genus *Escherichia*. *Eur. J. Biochem* 2002, 269, 3289–3295; [PubMed: 12084070] d)Slomiany BL; Murty V; Slomiany A, Isolation and characterization of oligosaccharides from rat colonic mucus glycoprotein. *J. Biol. Chem* 1980, 255, 9719–9723. [PubMed: 7430096]
- (17). a)Yu H; Cheng J; Ding L; Khedri Z; Chen Y; Chin S; Lau K; Tiwari VK; Chen X, Chemoenzymatic synthesis of GD3 oligosaccharides and other disialyl glycans containing natural and non-natural sialic acids. *J. Am. Chem. Soc* 2009, 131, 18467–18477; [PubMed: 19947630] b)Gilbert M; Brisson J-R; Karwaski M-F; Michniewicz J; Cunningham A-M; Wu Y; Young NM; Wakarchuk WW, Biosynthesis of ganglioside mimics in *Campylobacter jejuni* OH4384 identification of the glycosyltransferase genes, enzymatic synthesis of model compounds, and characterization of nanomole amounts by 600-MHz ¹H and ¹³C NMR analysis. *J. Biol. Chem* 2000, 275, 3896–3906. [PubMed: 10660542]
- (18). Liu X.-w.; Xia C; Li L; Guan W.-y.; Pettit N; Zhang H.-c.; Chen M; Wang PG, Characterization and synthetic application of a novel β 1,3-galactosyltransferase from *Escherichia coli* O55:H7. *Bioorg. Med. Chem* 2009, 17, 4910–4915. [PubMed: 19560364]
- (19). Ramakrishnan B; Qasba PK, Structure-based design of β 1,4-galactosyltransferase I (β 4Gal-T1) with equally efficient N-acetylglucosaminyltransferase activity point mutation broadens β 4Gal-T1 donor specificity. *J. Biol. Chem* 2002, 277, 20833–20839. [PubMed: 11916963]
- (20). Yu H; Chokhawala H; Karpel R; Yu H; Wu B; Zhang J; Zhang Y; Jia Q; Chen X, A multifunctional *Pasteurella multocida* sialyltransferase: a powerful tool for the synthesis of sialoside libraries. *J. Am. Chem. Soc* 2005, 127, 17618–17619. [PubMed: 16351087]
- (21). Fair RJ; Hahm HS; Seeberger PH, Combination of automated solid-phase and enzymatic oligosaccharide synthesis provides access to α (2,3)-sialylated glycans. *Chem. Commun* 2015, 51, 6183–6185.
- (22). a)Padler-Karavani V; Song X; Yu H; Hurtado-Ziola N; Huang S; Muthana S; Chokhawala HA; Cheng J; Verhagen A; Langereis MA; Kleene R; Schachner M; de Groot RJ; Lasanajak Y; Matsuda H; Schwab R; Chen X; Smith DF; Cummings RD; Varki A, Cross-comparison of protein recognition of sialic acid diversity on two novel sialoglycan microarrays. *J. Biol. Chem* 2012, 287, 22593–22608; [PubMed: 22549775] b)Song X; Yu H; Chen X; Lasanajak Y; Tappert

MM; Air GM; Tiwari VK; Cao H; Chokhawala HA; Zheng H; Cummings RD; Smith DF, A sialylated glycan microarray reveals novel interactions of modified sialic acids with proteins and viruses. *J. Biol. Chem* 2011, 286, 31610–31622. [PubMed: 21757734]

- (23). Lairson LL; Watts AG; Wakarchuk WW; Withers SG, Using substrate engineering to harness enzymatic promiscuity and expand biological catalysis. *Nature Chem. Biol* 2006, 2, 724–728. [PubMed: 17057723]

Scheme 1.

a) Common sialic acid forms and α 2–6-linkages; b) The known, and c) proposed enzymatic α 2–6-sialylation approaches.

Scheme 2.

Redox-controlled site specific α 2–6-sialylation of lacto-*N*-neohexaoside (LNnH) 11^a

^aReagents and conditions: [O], one-pot two enzyme oxidation module with commercial galactose oxidase and peroxidase; EM1, one-pot three-enzyme β 1–3-*N*-acetylglucosaminylation module with BINahK, EcGlmU and HpLgtA; EM2, one-pot three-enzyme β 1–4-galactosylation module with EcGalK, BLUSP and NmLgtB; EM3, one-pot two-enzyme α 2–6-sialylation module with NmCSS and Pd2,6ST, see Supporting Information for details.

Scheme 3.

Redox-controlled site specific α 2–6-sialylation with different sialic acid forms and substrate scope and application of redox-controlled site-specific α 2–6-sialylation strategy.^a

^aReagents and conditions: EM4, one-pot two-enzyme α 2–8-sialylation module with NmCSS and CjCstII; EM5, one-pot three-enzyme β 1–3-galactosylation module with EcGalK, BLUSP and EcWbgO; EM6, one-pot three-enzyme β 1–4-*N*-acetylgalactosaminylation module with B1NahK, EcGlmU and GalT1 Y289L; EM7, one-pot two-enzyme α 2–3-sialylation module with NmCSS and PmST1, see Supporting Information for details.